Among these markers, the tumor mutation burden (TMB), programmed death ligand 1 (PD-L1), and deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) have been validated in phase III clinical trials [1–3]. The gene discussed is CD274; the disease is neoplasm.